Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535227 | 1.00 | ESR1 (0.58) | ESR1ESR2PPARAMIFPTGS2 | |
| SCHEMBL4821206 | 0.89 | CA1 (0.56) | ESR1ESR2PPARAMIFPTGS2 | |
| SCHEMBL6419166 | 0.89 | PPARA (0.54) | ESR1ESR2PPARAPTGS2PPARG | |
| SCHEMBL977514 | 0.89 | PPARA (0.54) | ESR1ESR2PPARAPTGS2PPARG | |
| SCHEMBL977513 | 0.89 | PPARA (0.54) | ESR1ESR2PPARAPTGS2PPARG | |
| SCHEMBL7815559 | 0.88 | ESR1 (0.55) | ESR1ESR2PPARAMIFPTGS2 | |
| SCHEMBL1865433 | 0.86 | PPARA (0.48) | ESR1ESR2PPARAPPARGPPARD | |
| SCHEMBL1750767 | 0.86 | PPARA (0.51) | ESR1ESR2PPARAPPARGPPARD | |
| SCHEMBL3536105 | 0.86 | PPARA (0.48) | ESR1ESR2PPARAPPARGPPARD | |
| SCHEMBL1750768 | 0.86 | PPARA (0.51) | ESR1ESR2PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100376560-C | New tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | REDDY CHEMINOR INC (IN) | 2008-03-26 | — | — | CN | claimed |
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| CN-100376560-C | New tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | REDDY CHEMINOR INC (IN) | 2008-03-26 | — | — | CN | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-6440961-B1 | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-08-27 | — | — | US | disclosed |
| US-20020077320-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC. | 2002-06-20 | — | — | US | disclosed |
| CN-1352639-A | Novel tricyclic compounds and their use in medicine, process for their production and pharmaceutical composition containing them | REDDY RESEARCH FOUNDATION (IN) | 2002-06-05 | — | — | CN | disclosed |
| WO-2002024625-A2 | PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-03-28 | — | — | WO | disclosed |
| EP-1155006-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | Dr. Reddy's Research Foundation (IN) | 2001-11-21 | — | — | EP | disclosed |
| CN-1280575-A | Novel tricyclic compounds and their use as medicaments, process for their preparation and pharmaceutical compositions containing them | REDDY CHEMINOR INC (IN) | 2001-01-17 | — | — | CN | disclosed |
| EP-1049684-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000050414-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | DR.REDDY'S RESEARCH FOUNDATION (IN) | 2000-08-31 | — | — | WO | disclosed |
| US-6054453-A | HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. | REDD'S RESEARCH FOUNDATION (IN) | 2000-04-25 | — | — | US | disclosed |
| WO-1999019313-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077320-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | LIPC, GPR119, CPT1A | ESR1 3561/4885ESR2 2296/4885PPARA 281/4885 |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | ESR1 431/4885ESR2 151/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.